THIS WEEK'S FEATURE
Closely-held XOR Labs hopes to dramatically increase the number of lungs suitable for transplantation with its Ex-Vivo Lung Perfusion (EVLP) technology.
NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has developed a newly-patented delivery technology that increases the bioavailability and bioactivity of its Evolve line of gel-like cannabinoids for the treatment of pain, inflammation and anxiety.
Since developing and validating SETALUM, a versatile vascular sealant in 2013, closely-held, Paris-based Gecko Biomedical is now poised to seek FDA approval for SETALUM, validate new programs, and open a state-of-the-art manufacturing facility in Northern France.
FDA approval last week of Ventripoint Diagnostics’ (TSXV:VPT) VMS+ medical device with a four-chamber heart analysis system Is expected to change the paradigm of diagnosing and managing heart patients through a five-minute procedure that can be read in a cardiologist’s office in 10 minutes.
France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients.